Peter Attia

We're sort of extracting mechanistically from what we think these things do.

No RCTs.

What's the holdup?

I interviewed Tom seven years ago, and we had this exact same conversation.

Why do you think, especially for these cancers that are basically just killing machines, people are dead within a year of diagnosis.

Why is it so hard to do these trials?

But oncologists are not going to read that, right?

So the people that are on the front lines that are taking care of these patients.

Some of them are authors, so they've read it.

But again, what they want and what they need is a clinical trial that says this stack of interventions is going to double median survival.

So if someone came along and said, look, we're going to do all the things, we're going to rub curcumin on people's testicles and do all the things that are anecdotally supposed to help.

And it takes median survival from 11 months to 27 months.

Wow, that's huge.

Oh, and by the way, it's going to reduce the burden of seizures and it's going to reduce the catastrophic debilitating side effects of this tumor and its therapy.

I mean, it's going to become the standard of care, but the trial has to be done.

The trial has to be done.

It can't be these sort of one-off kludgy, like off in the corner little

nonsense trials that aren't getting attention.

So why is that?

Is GBM the wrong model then?